| 摘要 |
A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof, wherein the dashed line represents the presence or absence of a double bond; J is C-O or CHOH; A is -(CH<SUB>2</SUB>)<SUB>6</SUB>-, or cis -CH<SUB>2</SUB>CH-CH-(CH<SUB>2</SUB>)<SUB>3</SUB>-, wherein 1 or 2 carbons may be substituted with S or O; B is CO<SUB>2</SUB>H, or CO<SUB>2</SUB>R, CONR<SUB>2</SUB>, CONHCH<SUB>2</SUB>CH<SUB>2</SUB>OH, CON(CH<SUB>2</SUB>CH<SUB>2</SUB>OH)<SUB>2</SUB>, CH<SUB>2</SUB>OR, P(O)(OR)<SUB>2</SUB>, CONRSO<SUB>2</SUB>R, SONR<SUB>2</SUB>, or R is H, C<SUB>1-6 </SUB>alkyl; D is -(CH<SUB>2</SUB>)<SUB>n</SUB>-, -X(CH<SUB>2</SUB>)<SUB>n</SUB>, or -(CH<SUB>2</SUB>)<SUB>n</SUB>X-, wherein n is from 0 to 3 and X is S or O; and E is an aromatic or heteroaromatic moiety having from 0 to 4 substituents, said substituents each comprising from 1 to 6 non-hydrogen atoms is disclosed herein. Methods, compositions, and medicaments related thereto, as well as experimental results showing prostaglandin EP4 selective agonist activity for certain compounds disclosed herein, are also disclosed.
|
